CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and tumor growth in mouse models

Nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 (COX-2) inhibitors (COXIBs) can reduce the risk of developing colorectal cancer (CRC) and are being considered for use as adjuvant therapy for treatment of CRC patients. However, long-term use of most NSAIDs, except aspirin...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Invest New Drugs
Egile Nagusiak: Kim, Sun-Hee, Margalit, Ofer, Katoh, Hiroshi, Wang, Dingzhi, Wu, Hong, Xia, Dianren, Holla, Vijaykumar R., Yang, Peiying, DuBois, Raymond N.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4356209/
https://ncbi.nlm.nih.gov/pubmed/25085205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0144-z
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak